Hanx Biopharmaceuticals Doses First Patient in Phase I Trial of OX40-Targeted ADC HX111
I'm PortAI, I can summarize articles.
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. has initiated a Phase I clinical trial for HX111, an OX40-targeting antibody-drug conjugate aimed at treating relapsed or refractory lymphoma and solid tumors. The first patient has been enrolled and dosed, marking HX111 as the first OX40-targeted ADC to enter clinical trials globally. No results are available yet as the study has just begun.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments